Latest Information Update: 02 Sep 2016
At a glance
- Originator PharmaMax
- Class Antivirals
- Mechanism of Action Viral protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Viral infections
Most Recent Events
- 01 Aug 2016 Clinical trials in Viral infections in China (Intranasal) before August 2016
- 01 Aug 2016 PharmaMax has patent protection for RES 420 in China before August 2016